113 related articles for article (PubMed ID: 15472804)
1. Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers.
Hopkins RJ; Kramer WG; Blackwelder WC; Ashtekar M; Hague L; Winker-La Roche SD; Berezuk G; Smith D; Leese PT
Clin Infect Dis; 2004 Sep; 39(6):759-66. PubMed ID: 15472804
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review.
Hopkins RJ; Lane JM
Clin Infect Dis; 2004 Sep; 39(6):819-26. PubMed ID: 15472814
[TBL] [Abstract][Full Text] [Related]
3. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.
Wittek R
Int J Infect Dis; 2006 May; 10(3):193-201. PubMed ID: 16564720
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection.
Shearer JD; Siemann L; Gerkovich M; House RV
Antimicrob Agents Chemother; 2005 Jul; 49(7):2634-41. PubMed ID: 15980330
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetics of liquid and lyophilized formulations of IV RhIG immune globulin.
Sinclair CJ; Brooks W; Genereux MG
Biologicals; 2008 Jul; 36(4):256-62. PubMed ID: 18406165
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
[TBL] [Abstract][Full Text] [Related]
7. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response.
Lustig S; Maik-Rachline G; Paran N; Melamed S; Israely T; Erez N; Orr N; Reuveny S; Ordentlich A; Laub O; Shafferman A; Velan B
Vaccine; 2009 Mar; 27(11):1691-9. PubMed ID: 19195492
[TBL] [Abstract][Full Text] [Related]
8. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
[TBL] [Abstract][Full Text] [Related]
9. Henry Kempe and the birth of vaccinia immune globulin.
Bray M
Clin Infect Dis; 2004 Sep; 39(6):767-9. PubMed ID: 15472805
[No Abstract] [Full Text] [Related]
10. Identification and preliminary characterization of vaccinia virus (Dryvax) antigens recognized by vaccinia immune globulin.
Jones-Trower A; Garcia A; Meseda CA; He Y; Weiss C; Kumar A; Weir JP; Merchlinsky M
Virology; 2005 Dec; 343(1):128-40. PubMed ID: 16165184
[TBL] [Abstract][Full Text] [Related]
11. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
12. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia.
Goldsmith JC; Eller N; Mikolajczyk M; Manischewitz J; Golding H; Scott DE
Vox Sang; 2004 Feb; 86(2):125-9. PubMed ID: 15023182
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel vaccinia-neutralization assay based on reporter-gene expression.
Manischewitz J; King LR; Bleckwenn NA; Shiloach J; Taffs R; Merchlinsky M; Eller N; Mikolajczyk MG; Clanton DJ; Monath T; Weltzin RA; Scott DE; Golding H
J Infect Dis; 2003 Aug; 188(3):440-8. PubMed ID: 12870127
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy discovered after smallpox vaccination: Is vaccinia immune globulin appropriate?
Napolitano PG; Ryan MA; Grabenstein JD
Am J Obstet Gynecol; 2004 Dec; 191(6):1863-7. PubMed ID: 15592266
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
[TBL] [Abstract][Full Text] [Related]
17. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.
Subramanian GM; Cronin PW; Poley G; Weinstein A; Stoughton SM; Zhong J; Ou Y; Zmuda JF; Osborn BL; Freimuth WW
Clin Infect Dis; 2005 Jul; 41(1):12-20. PubMed ID: 15937757
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of therapeutic interventions for vaccinia virus keratitis.
Altmann S; Brandt CR; Murphy CJ; Patnaikuni R; Takla T; Toomey M; Nesbit B; McIntyre K; Covert J; Dubielzig R; Leatherberry G; Adkins E; Kodihalli S
J Infect Dis; 2011 Mar; 203(5):683-90. PubMed ID: 21278209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
